Ence Chuck's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed May 20, 2025
- Accession no.
- 0001213900-25-046086
- Filed
- May 20, 2025, 6:02 PM ET
- Trade date
- May 16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $103.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ence ChuckCIK 0001697779 | Officer (CA and CO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | PPurchaseAcquired | +228,961 | $0.4513F2 | +$103,330.1 | 267,931 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $0.401 to $0.4892 per share, inclusive.
Referenced by the price of 1 transaction in Table I.